Aquestive Therapeutics, Inc. (AQST)
NASDAQ: AQST · Real-Time Price · USD
4.120
+0.180 (4.57%)
At close: Jul 17, 2026, 4:00 PM EDT
4.121
+0.001 (0.02%)
After-hours: Jul 17, 2026, 7:58 PM EDT
Aquestive Therapeutics Stock Forecast
Stock Price Forecast
According to 9 analysts polled by S&P Global, Aquestive Therapeutics stock has a consensus rating of "Strong Buy" and an average price target of $8.89. The average 1-year stock price forecast is 115.78% higher than the current stock price, while the lowest is $6.00 (+45.63%) and the highest is $11 (+166.99%).
Price Target: $8.89 (+115.78%)
Analyst Consensus: Strong Buy
Price Target
ChartAnalyst Ratings
The average analyst rating for Aquestive Therapeutics stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Jan '26 | Feb '26 | Mar '26 | Apr '26 | May '26 | Jun '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 7 | 7 | 7 | 7 | 7 | 7 |
| Buy | 1 | 2 | 2 | 2 | 2 | 2 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 8 | 9 | 9 | 9 | 9 | 9 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Cantor Fitzgerald | Cantor Fitzgerald | Buy Maintains $11 | Buy | Maintains | $11 | +166.99% | Jun 26, 2026 |
| LifeSci Capital | LifeSci Capital | Buy Reiterates $9 | Buy | Reiterates | $9 | +118.45% | Jun 25, 2026 |
| Chardan Capital | Chardan Capital | Buy Reiterates $8 | Buy | Reiterates | $8 | +94.17% | Jun 25, 2026 |
| Leerink Partners | Leerink Partners | Buy Reiterates $9 | Buy | Reiterates | $9 | +118.45% | May 15, 2026 |
| Lake Street | Lake Street | Buy Maintains $6 | Buy | Maintains | $6 | +45.63% | May 15, 2026 |
Financial Forecast
Revenue This Year
50.51M
from 44.55M
Increased by 13.40%
Revenue Next Year
71.92M
from 50.51M
Increased by 42.38%
EPS This Year
-0.42
from -0.59
EPS Next Year
-0.45
from -0.42
EPS and Forward PE are based on non-GAAP adjusted numbers.